We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+17.46%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.94B
AUM Growth
+$209M
Cap. Flow
+$157M
Cap. Flow %
8.08%
Top 10 Hldgs %
37.79%
Holding
268
New
72
Increased
34
Reduced
55
Closed
76

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.3M
2
SONX
Sonendo, Inc.
SONX
+$7.34M
3
NTRA icon
Natera
NTRA
+$6.8M
4
AZTA icon
Azenta
AZTA
+$6.45M
5
QTRX icon
Quanterix
QTRX
+$5.89M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$22.4M
2
ILMN icon
Illumina
ILMN
+$11.7M
3
AZN icon
AstraZeneca
AZN
+$9.6M
4
OM icon
Outset Medical
OM
+$8.46M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.3M

Sector Composition

Rank Sector Weight
1 Healthcare 27.35%
2 Industrials 0.25%
3 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LONA
176
LeonaBio Inc
LONA
$73.9M
$246K 0.01%
7,770
-6,222
-44% -$196K
ALPN
177
DELISTED
Alpine Immune Sciences Inc
ALPN
$227K 0.01%
+30,924
New +$198K
SVRA icon
178
Savara
SVRA
$1.17B
$147K 0.01%
95,014
– –
MDVL
179
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$99.5K 0.01%
6,635
-7,647
-54% -$220K
CBIO
180
Crescent Biopharma
CBIO
$610M
$95.8K ﹤0.01%
+316
New +$46.6K
SLGCW
181
DELISTED
SomaLogic, Inc. Warrant
SLGCW
$81.8K ﹤0.01%
204,401
– –
RLMD icon
182
Relmada Therapeutics
RLMD
$503M
$77.6K ﹤0.01%
+22,233
New +$195K
APLT
183
DELISTED
Applied Therapeutics
APLT
$77.3K ﹤0.01%
+101,654
New +$80.4K
RLMD icon
184
CALL
Relmada Therapeutics
RLMD
$503M
$69.8K ﹤0.01%
+20,000
New +$176K
BVS icon
185
Bioventus
BVS
$1.17B
$65.3K ﹤0.01%
25,000
-561,696
-96% -$2.45M
TCDA
186
CALL
DELISTED
Tricida, Inc. Common Stock
TCDA
$45.9K ﹤0.01%
300,000
-18,100
-6% -$53.8K
TALKW
187
DELISTED
Talkspace Inc Warrant
TALKW
$31.1K ﹤0.01%
427,194
– –
EVAX
188
Evaxion A/S
EVAX
$25.6M
$29.9K ﹤0.01%
+337
New +$39.4K
MAPSW
189
DELISTED
WM TECHNOLOGY INC WTS
MAPSW
$5K ﹤0.01%
50,000
– –
SBIGW
190
DELISTED
SpringBig Holdings, Inc. Warrant
SBIGW
$211 ﹤0.01%
10,000
– –
ABBV icon
191
AbbVie
ABBV
$440B
– –
-50,000
Closed -$6.71M
AGL icon
192
Agilon Health
AGL
$1.45B
– –
-6,000
Closed -$3.51M
AKYA
193
DELISTED
Akoya BioSciences
AKYA
– –
-147,500
Closed -$1.73M
AMLX icon
194
Amylyx Pharmaceuticals
AMLX
$2.6B
– –
-68,652
Closed -$1.93M
ARDX icon
195
CALL
Ardelyx
ARDX
$1.03B
– –
-200,000
Closed -$238K
ARDX icon
196
Ardelyx
ARDX
$1.03B
– –
-50,000
Closed -$60K
ATAI icon
197
AtaiBeckley Inc
ATAI
$2.68B
– –
-721,824
Closed -$2.39M
ATRC icon
198
AtriCure
ATRC
$2.22B
– –
-152,834
Closed -$5.98M
AZN icon
199
AstraZeneca
AZN
$246B
– –
-87,500
Closed -$9.6M
BDX icon
200
PUT
Becton Dickinson
BDX
$50B
– –
-32,000
Closed -$7.13M
6 7
8
9 10

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q4 2022 Portfolio in Review

As of Q4 2022, Pura Vida Investments held 268 positions worth $1.94B, up 12% from $1.73B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Pura Vida Investments deployed $157M of net new capital in Q4 2022, opening 72 new positions and adding to 34 existing holdings. Its largest new stake was Natera: 165,000 shares worth $6.63M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 35% a quarter earlier, followed by Industrials and Materials.

On the sell side, the largest reduction was United Therapeutics, an estimated $22.4M trimmed.

  • Pura Vida Investments's largest Q4 2022 buy was Natera: 165,000 shares worth $6.63M.
  • Pura Vida Investments added most to Biogen in Q4 2022, an estimated $16.3M increase.
  • Pura Vida Investments's biggest Q4 2022 reduction was United Therapeutics, cutting an estimated $22.4M.
  • Pura Vida Investments fully exited Illumina in Q4 2022, selling an estimated $11.7M.
  • Pura Vida Investments's ten largest holdings make up 38% of its $1.94B portfolio in Q4 2022.
  • Pura Vida Investments opened 72 new positions and closed 76 in Q4 2022.
  • Pura Vida Investments's portfolio value rose 12% quarter-over-quarter to $1.94B.

Based on Pura Vida Investments's 13F filing for Q4 2022, filed 14 Feb 2023.